Biophoundry
Biophoundry specializes in advancing scalable engineered phage-based solutions for therapeutics, diagnostics, and bio-molecular engineering. It is shifting the paradigm from phage discovery to phage design. Its team leverages expertise in synthetic biology, machine learning, and data science to accelerate the development of precision antibiotics and address critical healthcare challenges such as antimicrobial resistance.
Biophoundry
Biophoundry is currently seeking investment
Biophoundry is seeking a seed investment in the range of 1m-5m
What We Do
Phax Forge: Rapid Phage Engineering
Biophoundry has developed phage engineering workflows applicable to diverse clinical bacteria. Engineering methods include genome modification and post-translational modification (e.g., for tissue targeted delivery or fluorescent tagging) to improve safety and efficacy in phage applications both clinical and non-clinical.
Capability includes:
-Gene deletion/insertion
-Point mutations or insertions
-Addition of genetic payload (e.g., antimicrobial enhancers, immunomodulators, reporter genes)
Target bacteria: E. coli, Klebsiella, Pseudomonas, Acinetobacter, C. difficile
Phax Discovery: Digital-to-lab phage discovery
Biophoundry mines genome data to identify useful phage for bacterial killing. Paired with high-throughput validation assays, Phax discovery enables building and updating phage libraries with verified host range, overcoming a major bottleneck in phage applications.
Cell-free bacteriophage synthesis (CFBS)
Biophoundry has built upon establish methods for in vitro protein synthesis to enable production of phage using cell-free, all in vitro methods with the primary input of phage DNA. The result is rapid phage production with reduced downstream processing, getting on-demand phage to patients faster.
Phax Forge: Rapid Phage Engineering
Biophoundry has developed phage engineering workflows applicable to diverse clinical bacteria. Engineering methods include genome modification and post-translational modification (e.g., for tissue targeted delivery or fluorescent tagging) to improve safety and efficacy in phage applications both clinical and non-clinical. Capability includes: -Gene deletion/insertion -Point mutations or insertions -Addition of genetic payload (e.g., antimicrobial enhancers, immunomodulators, reporter genes) Target bacteria: E. coli, Klebsiella, Pseudomonas, Acinetobacter, C. difficile
Phax Discovery: Digital-to-lab phage discovery
Biophoundry mines genome data to identify useful phage for bacterial killing. Paired with high-throughput validation assays, Phax discovery enables building and updating phage libraries with verified host range, overcoming a major bottleneck in phage applications.
Cell-free bacteriophage synthesis (CFBS)
Biophoundry has built upon establish methods for in vitro protein synthesis to enable production of phage using cell-free, all in vitro methods with the primary input of phage DNA. The result is rapid phage production with reduced downstream processing, getting on-demand phage to patients faster.
Application Area
Infectious Diseases
Biologics
Vaccines
Digital Health Technologies
Services
Routes of Administration
Drugs
Key People
News & Updates
Appointment of Michael Stam, a Senior ML Scientist, to advance and validate phage platform development.
Relocation of laboratory operations to Biolabs Chapel Hill.
Completion of project for the development of a phage platform pipeline.
Appointment of Michael Stam, a Senior ML Scientist, to advance and validate phage platform development.
Relocation of laboratory operations to Biolabs Chapel Hill.
Completion of project for the development of a phage platform pipeline.